遗传性肺动脉高压和药物遗传学

Genetics and pharmacogenomics in pulmonary arterial hypertension.

机构信息

Division of Pulmonary and Critical Care Medicine, University of Utah, Maxwell Wintrobe Research Building, 26 North Medical Drive, Salt Lake City, UT 84132, USA.

出版信息

Heart Fail Clin. 2012 Jul;8(3):319-30. doi: 10.1016/j.hfc.2012.04.008.

DOI:10.1016/j.hfc.2012.04.008

PMID:22748897

Abstract

Pulmonary arterial hypertension (PAH) is an uncommon disease in the general population, but a disease with significant morbidity and mortality. The prevalence of heritable PAH (HPAH) remains unknown. The reason for incomplete penetrance of HPAH is not well understood. A patient's clinical response to disease-specific therapy is complex, involving the severity of the patient's disease, other comorbidities, appropriateness of the prescribed therapy, and patient compliance. Warfarin is often used as an adjuvant therapy in patients with PAH.

摘要

肺动脉高压（PAH）在普通人群中较为少见，但却是一种发病率和死亡率都很高的疾病。遗传性 PAH（HPAH）的患病率尚不清楚。HPAH 不完全外显的原因尚不清楚。患者对特定疾病治疗的临床反应较为复杂，涉及患者疾病的严重程度、其他合并症、所开治疗的恰当性以及患者的依从性。华法林常用于 PAH 患者的辅助治疗。